Morgan Stanley
APRE icon

Morgan Stanley’s Aprea Therapeutics APRE Stock Holding History

Morgan Stanley’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.7K Buy
25,830
+3,500
+16% +$2.92K ﹤0.01% 6808
2026
Q1 		$17K Sell
22,330
-54,700
-71% -$43K ﹤0.01% 6787
2025
Q4 		$65.7K Buy
77,030
+11,222
+17% +$13.8K ﹤0.01% 6352
2025
Q3 		$97.1K Buy
65,808
+2,477
+4% +$4.08K ﹤0.01% 6166
2025
Q2 		$107K Buy
63,331
+30,523
+93% +$52K ﹤0.01% 6102
2025
Q1 		$66.9K Sell
32,808
-4,000
-11% -$12.5K ﹤0.01% 6176
2024
Q4 		$121K Buy
36,808
+2,600
+8% +$8.69K ﹤0.01% 5979
2024
Q3 		$94.1K Buy
34,208
+4,390
+15% +$15.5K ﹤0.01% 6033
2024
Q2 		$121K Buy
29,818
+3,000
+11% +$15.5K ﹤0.01% 5893
2024
Q1 		$179K Buy
26,818
+9,600
+56% +$59.7K ﹤0.01% 5771
2023
Q4 		$80.9K Buy
17,218
+2,656
+18% +$10.9K ﹤0.01% 6025
2023
Q3 		$60.7K Sell
14,562
-722
-5% -$2.63K ﹤0.01% 6083
2023
Q2 		$48.1K Buy
15,284
+733
+5% +$2.73K ﹤0.01% 6227
2023
Q1 		$64.6K Buy
14,551
+758
+5% +$5.6K ﹤0.01% 6191
2022
Q4 		$91.3K Sell
13,793
-1,808
-12% -$19.1K ﹤0.01% 6015
2022
Q3 		$202K Sell
15,601
-1,991
-11% -$35.3K ﹤0.01% 5723
2022
Q2 		$264K Buy
17,592
+5,245
+42% +$121K ﹤0.01% 5754
2022
Q1 		$459K Sell
12,347
-3,964
-24% -$162K ﹤0.01% 5456
2021
Q4 		$936K Buy
16,311
+7,063
+76% +$624K ﹤0.01% 5119
2021
Q3 		$945K Sell
9,248
-41,741
-82% -$3.79M ﹤0.01% 5081
2021
Q2 		$4.97M Buy
50,989
+1,083
+2% +$100K ﹤0.01% 3781
2021
Q1 		$5.09M Buy
49,906
+26,255
+111% +$3.06M ﹤0.01% 3393
2020
Q4 		$2.33M Buy
23,651
+20,262
+598% +$9.63M ﹤0.01% 4025
2020
Q3 		$1.63M Sell
3,389
-144
-4% -$80.6K ﹤0.01% 3836
2020
Q2 		$2.74M Buy
3,533
+3,508
+14,032% +$2.3M ﹤0.01% 3286
2020
Q1 		$17K Sell
25
-645
-96% -$473K ﹤0.01% 5860
2019
Q4 		$615K Buy
+670
New +$369K ﹤0.01% 4813

Other funds holding APRE

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Morgan Stanley's APRE Position: Q2 2026 in Review

Morgan Stanley increased its Aprea Therapeutics (APRE) stake by 16% in Q2 2026, buying an estimated $2.92K and bringing the position to 25,830 shares worth $20.7K. The position accounts for ﹤0.01% of the portfolio, ranked #6808.

Morgan Stanley first reported a position in APRE in Q4 2019 and has held it in 27 quarters since. The position peaked at $5.09M in Q1 2021. 28 funds tracked by Wall St. Rank hold APRE as of Q2 2026.

  • Morgan Stanley held 25,830 shares of Aprea Therapeutics worth $20.7K as of Q2 2026.
  • Morgan Stanley bought 3,500 Aprea Therapeutics shares in Q2 2026, an estimated $2.92K.
  • Aprea Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6808 holding.
  • Morgan Stanley first reported a position in Aprea Therapeutics in Q4 2019 and has held it in 27 quarters since.
  • Morgan Stanley's Aprea Therapeutics position peaked at $5.09M in Q1 2021.
  • 28 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.